HC Wainwright Has Optimistic Outlook of Septerna Q3 Earnings

Key Points

• HC Wainwright has increased its earnings per share estimate for Septerna's Q3 2025 from $0.72 to $1.15, with a maintained "Buy" rating and a target price of $26.00.
• Septerna reported Q2 results that missed consensus estimates, posting a loss of ($0.56) per share against an expected loss of ($0.05), with revenue of only $0.12 million compared to an anticipated $22.50 million.
• Analyst sentiment is mixed, with Cantor Fitzgerald and Wells Fargo raising their price targets, while Wall Street Zen downgraded Septerna from "hold" to "sell," resulting in an average rating of "Moderate Buy" across analysts.

Septerna, Inc. (NASDAQ:SEPN - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for shares of Septerna in a research note issued on Monday, August 18th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $1.15 per share for the quarter, up from their prior estimate of $0.72. HC Wainwright currently has a "Buy" rating and a $26.00 price target on the stock. The consensus estimate for Septerna's current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna's Q4 2025 earnings at $0.87 EPS, Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.84) EPS and FY2026 earnings at ($1.86) EPS.

Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51). The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%.

Other equities research analysts have also issued reports about the stock. Wells Fargo & Company upped their price target on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a report on Friday, May 16th. Cantor Fitzgerald lifted their price target on shares of Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Finally, Wall Street Zen downgraded shares of Septerna from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, Septerna presently has an average rating of "Moderate Buy" and an average target price of $26.75.

Septerna Stock Performance

SEPN traded up $0.29 on Wednesday, hitting $11.99. 362,953 shares of the company were exchanged, compared to its average volume of 228,883. Septerna has a 12 month low of $4.17 and a 12 month high of $28.99. The stock has a market capitalization of $534.51 million and a PE ratio of -1.19. The firm has a fifty day simple moving average of $11.64 and a two-hundred day simple moving average of $9.05.

Hedge Funds Weigh In On Septerna

Institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC purchased a new stake in shares of Septerna during the 4th quarter valued at about $25,000. Legal & General Group Plc bought a new stake in Septerna during the fourth quarter worth approximately $42,000. Summit Investment Advisors Inc. bought a new stake in Septerna during the fourth quarter worth approximately $45,000. KLP Kapitalforvaltning AS purchased a new stake in Septerna during the first quarter valued at approximately $49,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Septerna in the 4th quarter valued at approximately $52,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.